As a pioneer in the production of high-quality pharmaceuticals, Imexpharm consistently accompanies the medical community through scientific and professional initiatives, affirming its role as a leading pharmaceutical company dedicated to public health.
Supporting healthcare professionals
In the last two weeks of March 2025, Imexpharm once again demonstrated its pioneering spirit and long-term commitment over nearly five decades of supporting the healthcare sector and the community, by serving as the sponsor for two major medical science events: The 41st Annual Otolaryngology Scientific Conference (March 21–23 in Da Nang); and The Scientific Conference celebrating the 20th Anniversary of Thien Hanh General Hospital (March 27 in Buon Ma Thuot).
At the 41st Otolaryngology Scientific Conference, one of the most prestigious annual events in the fields of ENT, head and neck surgery, and pediatrics, Imexpharm participated as a key sponsor, reinforcing its mission to "Provide highly effective solutions for public health."
With the theme “Updates in Diagnosis and Treatment of ENT / Head and Neck Surgery – Pediatrics – Audiology”, the 2025 conference brought together more than 600 leading experts, doctors, and researchers nationwide. The program featured 72 in-depth scientific reports from department heads, lecturers, and professional associations, offering diverse perspectives on pressing issues in today’s treatments. Notably, respiratory tract infections and the rational use of antibiotics remained hot topics in the context of growing antibiotic resistance.
On March 27, Imexpharm continued its journey to Buon Ma Thuot to join Thien Hanh General Hospital in celebrating its 20th anniversary, a milestone for the largest private hospital in the Central Highlands. The accompanying scientific conference brought together 70 experts and speakers from various medical fields, presenting 72 scientific reports that shared advancements in treatment and healthcare management.
As a long-time partner of both public and private hospitals across the country, Imexpharm deeply values these important milestones in the medical field, viewing them as opportunities to share knowledge and foster professional connections.
“We don’t just deliver high-quality pharmaceuticals; we accompany doctors in accessing the latest knowledge and treatment methods. Our presence at leading scientific conferences is proof of our enduring commitment to enhancing treatment quality and community health,” shared an Imexpharm representative.
Strong Investment in Research & Development (R&D)
Holding a leading position in high-quality pharmaceutical manufacturing with 3 EU-GMP factory clusters and 12 EU-GMP production lines, Imexpharm is not only a top antibiotic manufacturer and distributor in Vietnam but also a long-term partner in bridging scientific research, clinical practice, and internationally standardized product development.
This direction aligns with Vietnam's National Strategy on Protection, Care, and Improvement of People’s Health to 2030, with a vision to 2045, in which the government emphasizes scientific research and technological application in medicine as a core goal to strengthen and modernize the national healthcare system.
According to the Ministry of Health, Vietnam's capabilities in medical research and technology application are approaching international standards, with the country now contributing to global clinical research networks in multiple domains. A key goal is to develop medical research focused on community health, particularly in areas such as infectious diseases, chronic conditions, and advanced treatment solutions.
Over nearly 50 years of development, Imexpharm has consistently made strong investments in R&D, recognizing it as a fundamental pillar of sustainable growth. In 2024, the company launched 24 new products and implemented 98 R&D on-going projects, aiming to significantly expand its portfolio of high-tech, high-value pharmaceuticals in 2025. Notably, Imexpharm received 28 marketing authorizations in European markets for 11 products, marking a critical milestone in its global expansion strategy.
In line with its vision to expand into non-antibiotic treatments and chronic disease therapeutics, Imexpharm is currently building the Cat Khanh Pharmaceutical Complex in Quang Khanh Industrial Zone, Dong Thap. In addition to conventional formulations, the company is developing advanced technologies such as lyophilization, orally disintegrating tablets, and multi-dose powders to boost competitiveness and diversify its future product range.
These achievements are the result of a long-term investment strategy focused on European-standard pharmaceutical production—particularly in antibiotics, a strategic strength of the company. Imexpharm emphasizes producing antibiotics from fermented enzymatic APIs, ensuring strict control over impurities such as nitrosamines, residual solvents, and heavy metals to guarantee high safety and quality. Flagship products such as Claminat, Bactamox, and Biocemet DT have demonstrated superior efficacy in respiratory infection treatment across various patient groups.
Alongside internal capability development, Imexpharm is actively expanding international cooperation to enhance production and product development. The company is a strategic partner of global pharmaceutical groups including Genuone Sciences, Pharmascience, and Sanofi, and is also applying WHO Good Practices for R&D Facilities to align its systems with international standards.
All of these efforts aim toward Imexpharm’s strategic goal for 2025: "Connecting Science – Resilient Growth."